-
Select a Region
-
- Get Involved Now
- Conference Details
- Conference Partners
- Delegate Information
|
|
|
|
Chirality in Drug Compounds
Reduce Lab Costs and Drive Efficiency through Effective use of Chiral Synthesis, Resolution and Crystallisation Techniques
December 1 - 2, 2008 · Cafe Royal, London, UK
|
|
|
Benefits of Attending
Register yourself and a team online now!
Become a free member of Pharma IQ's online community.
Early Bird Discount
Register and pay by 15th August, 2008 and receive up to £300 off!
Download the Brochure!
Over 2/3 of new drugs reaching the market are chiral and a significant percentage of these are produced using chiral separation techniques
Frank Leusen, Bradford Institute of Pharmaceutical Innovation
The number of chiral synthetic drugs, which are administered enantiomerically pure, has increased steadily up to the present value of 80 %*
Whether you are working hands on in the lab, or overseeing strategic management, this unparalleled, case study-heavy event will ensure you reach your goals.
Chirality in Drug Compounds is launching in 2008 after the success of the focus day run at our Polymorphism and Crystallisation event in March of this year. We listened to the feedback from our audience and broadened the subject area from Crystallisation, to include Resolution and Separation, all three subject areas are covered extensively.
Who should attend?
Scientists
- Achieve efficacy of pharmaceutical compounds through effective molecular recognition and separation techniques
- Increase percentage yield by creating enantiopure solid state forms
- Explore biocatalysis and asymmetric hydrogenation in synthesis to provide new chiral structures to expand research options
Lab Heads/Strategic Management
- Minimise research costs by finding the optimum strategy to employ when dealing with chiral separation
- Reduce time to marketing by streamlining your research processes
- Drive efficiency and cut waste in production processes and separation techniques to employ the most cost effective methods in you research projects
Benefits
By attending Chirality in Drug Compounds, we will show you how to
- Cut research costs
- Reduce time to market
- Achieve efficacy
- Expand research options
Confirmed speakers
- Professor Gerard Coquerel, Material Chemistry, University of Rouen
- Dr Frank Leusen, Senior Scientist, Bradford Institute of Pharmaceutical Innovation
- Professor Meir Lahav, The Margaret Thatcher Professor of Chemistry, Department of Materials and Interfaces, Weizmann Institute
- Dr Peter Dunn, Green Chemistry Lead, Pfizer
- Dr Heike Lorenz, Max-Planck-Institute for Dynamics of Complex Technical Systems
- Dr Mike Song, Solid-State research Scientist, Organon, Part of Schering-Plough Corp.
- Professor Kevin Roberts, Brotherton Professor of Chemical Engineering, Department of Chemistry, University of Leeds
- Sharon Bowden, Principal Crystallisation Scientist, AstraZeneca
- Professor Timothy Donohoe, Department of Chemistry, Oxford University
- Dr Panagiotis (Panos) Karamertzanis, Senior Post-Doctoral Associate, Department of Chemistry, University College London
- Dr Paul Rodwell, Senior Research Scientist, Research Analytics, Pfizer
- Dr Ludwig Goetelen, Scientist, Johnson and Johnson
- Dr Veronique Pinilla, Senior Group Leader, Chromatography, UCB Group
Click here for speaker bios
If you are not yet ready to register, feel free to request a reminder nearer the time.
Conference Partners
| Featured Exhibitors |
Media Partners |
|
|
[ Register Now ]
· [ Next: Conference Day One: 1st December, 2008 ]
|
|
|
|
|